Last reviewed · How we verify
Azithromycin and Chloroquine
At a glance
| Generic name | Azithromycin and Chloroquine |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat. (PHASE4)
- Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus (PHASE3)
- Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 (PHASE1, PHASE2)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection (PHASE3)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients (PHASE2)
- Adverse Events Related to Treatments Used Against Coronavirus Disease 2019
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin and Chloroquine CI brief — competitive landscape report
- Azithromycin and Chloroquine updates RSS · CI watch RSS
- Pfizer portfolio CI